Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Inosine pranobex is a synthetic antiviral and immunomodulatory drug composed of inosine and dimepranol acedoben (a salt of acetamidobenzoic acid and dimethylaminoisopropanol) in a 1:3 ratio. It enhances host immune responses by stimulating T-cell lymphocyte proliferation, increasing natural killer cell activity, and boosting pro-inflammatory cytokines such as IL-2 and interferon-gamma. These effects restore deficient immune responses in immunosuppressed patients. Inosine pranobex also inhibits the growth of several viruses by affecting viral RNA levels. Clinically, it is used to treat subacute sclerosing panencephalitis (SSPE), mucocutaneous herpes simplex virus infections (types 1 and 2), genital warts (as adjunctive therapy), human papillomavirus infection, cytomegalovirus infection, Epstein–Barr virus infection, acute viral respiratory infections including influenza and measles, as well as for general immunosuppressed states[1][2][4][5].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on inosine pranobex (Themis Medicare Limited).